Thinking of joining a study?

Register your interest

Become a volunteer?

NCT04459468 | RECRUITING | Hepatocellular Carcinoma

Identify Proteomic Biomarkers for Outcome Prediction of Locoregional Treatments for HCC
Sponsor:

University of Texas Southwestern Medical Center

Information provided by (Responsible Party):

Squirrel

Brief Summary:

This study will enroll patients with hepatocellular carcinoma being planned for TACE or other standard of care treatment (such as denovo ablation or Y90) and obtain blood samples pre and post treatment procedure for biomarker identification using bead based X-aptamer library. No intervention is planned.

Condition or disease

Hepatocellular Carcinoma

Intervention/treatment

Lipiodol

Detailed Description:

This is a prospective, non-blinded, multi-arm study. Patients at 18 - 70 years old with liver cancer will be enrolled. The approach is to identify novel proteomic biomarkers for HCC patients treated with Lipiodol TACE, denovo ablation or Y90 using beads-based X-aptamer library, then validate and create a biomarker panel that can be used to predict the outcome of HCC post treatment. Lipiodol TACE, denovo ablation, or Y90 will be done as standard of care and the only thing done as research will be blood draws pre and post-TACE.

Study Type : OBSERVATIONAL
Estimated Enrollment : 60 participants
Official Title : Identify Proteomic Biomarkers for Outcome Prediction of Locoregional Treatments for Hepatocellular Carcinoma (HCC)
Actual Study Start Date : 2022-11-04
Estimated Primary Completion Date : 2025-06
Estimated Study Completion Date : 2025-12

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: 18 Years to 70 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers:
Criteria
Inclusion Criteria
  • 1. Ability to understand and the willingness to sign a written informed consent.
  • 2. Male or female aged 18-70years.
  • 3. Diagnosed with primary or metastatic liver cancer.
  • 4. Scheduled to undergo Lipoidal TACE, denovo ablation, or Yttrium-90 (Y90) radioembolization as part of standard of care.
Exclusion Criteria
  • Subjects who have received chemotherapy, radiation or surgery for HCC.
Identify Proteomic Biomarkers for Outcome Prediction of Locoregional Treatments for HCC

Location Details

NCT04459468

Please Choose a site

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations

RECRUITING

United States, Texas

UT Southwestern Medical Center

Dallas, Texas, United States, 75390